• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

肝动脉栓塞术联合长效奥曲肽降低中低级别神经内分泌瘤肝转移负荷的疗效及安全性分析

Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis

摘要:

目的 探讨肝动脉栓塞术(TAE)联合长效奥曲肽对中低级别神经内分泌瘤肝转移(NETLM)的疗效及安全性.方法 回顾性分析2014年10月至2018年8月中山大学附属第一医院诊治的29例NETLM患者,年龄25~ 69(50±11)岁,男12例、女17例.所有病例均病理确诊,病例资料完整.其中17例TAE联合长效奥曲肽(联合治疗组),12例单纯长效奥曲肽治疗(单纯治疗组).根据实体瘤反应评价标准1.1 (RECIST 1.1)评价肝内病灶疗效,比较两组客观反应率(ORR),并评价其安全性.结果 联合治疗组部分缓解13例,病情稳定4例;单纯治疗组部分缓解1例,病情稳定9例,疾病进展2例.两组ORR差异有统计学意义(13/17比1/12,P<0.01).TAE术后主要不良反应为栓塞后综合征,包括腹痛(12/17)、呕吐(6/17)、发热(4/17)、转氨酶升高(8/17)及胆红素升高(3/17)等.1例患者出现肿瘤溶解综合征.结论 相比单纯应用长效奥曲肽,TAE联合长效奥曲肽更有效降低NET肝转移肿瘤负荷,并具有良好的安全性和耐受性.

更多
abstracts:

Objective To evaluate the tumor burden reducing efficacy and safety of transcatheter arterial embolization (TAE) combined with octreotide LAR on neuroendocrine tumor liver metastasis (NETLM).Methods Twenty-nine NETLM patients treated in the First Affiliated Hospital of Sun Yat-sen University from October 2014 to August 2018 were retrospectively recruited,including 12 males and 17 females.The mean age was 25-69(50±11) years.All patients were histologically proved as well-differentiated NET liver metastasis.Seventeen patients underwent combined treatment of TAE plus octreotide LAR (combined group) and 12 patients treated with only octreotide LAR (control group).Response of hepatic lesions were assessed according to RECIST 1.1.Objective response rates (ORR) of two groups were compared and analyzed.Safety and tolerance to TAE were also evaluated.Results There were 13 PR and 4 SD in combined group,but only 1 PR and 9 PD in the control group.The ORR between the two groups were significantly different (13/17 vs 1 / 12,P < 0.0 l).The main complication post TAE was post embolization syndrome,including abdominal pain (12/17),vomiting (6/17),fever (4/17),elevated transaminase (8/17) and bilirubinemia (3/17).Tumor lysis syndrome was observed in one patient.Conclusion Compared to administration of octreotide LAR,TAE combined with octreotide LAR can effectively reduce tumor burden in patients with NETLM.TAE is safe and well-tolerated.

More
  • 浏览:80
  • 下载:237

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷